Structure-activity study to develop cationic lipid-conjugated haloperidol derivatives as a new class of anticancer therapeutics

Journal of Medicinal Chemistry

Volumn 54, Issue 7, 2011, Pages 2378-2390

  Pal, Krishnendu ^a   Pore, Subratakumar ^a   Sinha, Sutapa ^b   Janardhanan, Rajiv ^b   Mukhopadhyay, Debabrata ^b   Banerjee, Rajkumar ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ALANINE; CARBON; CASPASE 3; DELTA OPIATE RECEPTOR; HALOPERIDOL; HALOPERIDOL LIPID CONJUGATE DERIVATIVE; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG DISCOVERY; ENDOTHELIUM, VASCULAR; GENE KNOCKDOWN TECHNIQUES; HALOPERIDOL; HUMANS; LIPIDS; MALE; MICE; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, SIGMA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953797511     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101530j     Document Type: Article

References (28)

1. Wolfe, S. A., Jr.; Culp, S. G.; De Souza, E. B. Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary Endocrinology 1989, 124, 1160-1172 (Pubitemid 19082680)
2. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling Eur. J. Pharmacol. 1994, 268, 9-18
3. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines Cancer Res. 1995, 55, 408-13
4. John, C. S.; Bowen, W. D.; Saga, T.; Kinuya, S.; Vilner, B. J.; Baumgold, J.; Paik, C. H.; Reba, R. C.; Neumann, R. D.; Varma, V. M.; McAfee, J. G. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide J. Nucl. Med. 1993, 34, 2169-2175 (Pubitemid 24002961)
5. 125I]- N -(N -benzylpiperidin-4-yl)-4-iodobenzamide, a new sigma receptor radiopharmaceutical: high affinity binding to MCF-7 breast tumor cells J. Med. Chem. 1994, 37, 1737-1739 (Pubitemid 24219763)
6. 125I]- N -(N -benzylpiperidine-4-yl)-4-iodobenzmide: a high affinity sigma receptor ligand for potential imaging of breast cancer Cancer Res. 1995, 55, 3022-3027
7. 125I] N -[2-(4-iodophenyl)ethyl]- N -methyl-2-(1-piperidinyl)ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors Nucl. Med. Biol. 1996, 23, 761-766 (Pubitemid 26342479)
8. John, C. S.; Vilner, B. J.; Geyer, B. C.; Moody, T.; Bowen, W. D. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors Cancer Res. 1999, 59, 4578-4583 (Pubitemid 29428962)
9. 125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer Nucl. Med. Biol. 1999, 26 (4) 377-382 (Pubitemid 29254023)
10. Wheeler, K. T.; Wang, L. M.; Wallen, C. A.; Childers, S. R.; Cline, J. M.; Keng, P. C.; Mach, R. H. Sigma-2 receptors as a biomarker of proliferation in solid tumours Br. J. Cancer 2000, 82, 1223-1232 (Pubitemid 30128883)
11. Zamora, P. O.; Moody, T. W.; John, C. S. Increased binding to sigma sites of N -[1′ (2-piperidinyl)ethyl)-4-[I-125]-iodobenzamide (I-125-PAB) with onset of tumor cell proliferation Life Sci. 1998, 63, 1611-1618 (Pubitemid 28483124)
12. Crawford, K. W.; Bowen, W. D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines Cancer Res. 2002, 62, 313-322 (Pubitemid 34074021)
13. Brent, P. J.; Pang, G. T. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture Eur. J. Pharmacol. 1995, 278, 151-160
14. Wei, Z.; Mousseau, D. D.; Dai, Y.; Cao, X.; Li, X. M. Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS Pharmacogenomics J. 2006, 6, 279-288 (Pubitemid 44137955)
15. Nordenberg, J.; Perlmutter, I.; Lavie, G.; Beery, E.; Uziel, O.; Morgenstern, C.; Fenig, E.; Weizman, A. Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines Int. J. Oncol. 2005, 27, 1097-1103
16. Dai, Y.; Wei, Z.; Sephton, C. F.; Zhang, D.; Anderson, D. H.; Mousseau, D. D. Haloperidol induces the nuclear translocation of phosphatidylinositol 3′-kinase to disrupt Akt phosphorylation in PC12 cells J. Psychiatry Neurosci. 2007, 32, 323-330 (Pubitemid 47492757)
17. Mukherjee, A.; Prasad, T. K.; Rao, N. M.; Banerjee, R. Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells J. Biol. Chem. 2005, 280, 15619-15627 (Pubitemid 40616679)
18. Karmali, P. P.; Chaudhuri, A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises Med. Res. Rev. 2007, 27, 696-722 (Pubitemid 47282449)
19. Mukherjee, A.; Narayan, K. P.; Pal, K.; Kumar, J. M.; Rangaraj, N.; Kalivendi, S. V.; Banerjee, R. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor Mol. Ther. 2009, 17, 623-631
20. 123I-MEL037, for malignant melanoma J. Nucl. Med. 2007, 48, 1348-1356 (Pubitemid 47242801)
21. Kim, N. R.; Park, S. W.; Lee, J. G.; Kim, Y. H. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 633-642 (Pubitemid 351312355)
22. Wei, Z.; Qi, J.; Dai, Y.; Bowen, W. D.; Mousseau, D. D. Haloperidol disrupts Akt signalling to reveal a phosphorylation-dependent regulation of pro-apoptotic Bcl-XS function Cell. Signallling 2009, 21, 161-168
23. 2+] in colon and mammary adenocarcinoma cells Biochem. Biophys. Res. Commun. 1996, 219, 219-226
24. Kim, R.; Emi, M.; Tanabe, K. Role of mitochondria as the gardens of cell death Cancer Chemother. Pharmacol. 2006, 57, 545-553 (Pubitemid 43237837)
25. Gross, A.; McDonnell, J. M.; Korsmeyer, S. J. BCL-2 family members and the mitochondria in apoptosis Genes Dev. 1999, 13, 1899-1911 (Pubitemid 29407357)
26. Testa, J. R.; Bellacosa, A. Akt plays a central role in tumorigenesis Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10983-10985 (Pubitemid 32928669)
27. Riesterer, O.; Zingg, D.; Hummerjohann, J.; Bodis, S.; Pruschy, M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells Oncogene 2004, 23, 4624-4635 (Pubitemid 38850410)
28. Sinha, S.; Roy, S.; Reddy, B. S.; Pal, K.; Sudhakar, G.; Iyer, S.; Dutta, S.; Wang, E.; Vohra, P. K.; Roy, K. R.; Reddanna, P.; Mukhopadhyay, D.; Banerjee, R. A lipid modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis. Mol. Cancer Res. [Online early access]. DOI: 10.1158/1541-7786.MCR-10-0526. Published Online: February 2, 2011.